Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments) and Diagnostics (Imaging, Biopsy, Endoscopic Ultrasound, and Other Diagnostics), and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023

Code : CMI5473

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Pancreatic Cancer Therapeutics and Diagnostic Market: Key Developments

In January 2022, Zai Lab Limited announced the successful treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase III trial is evaluating the efficacy of tumor treating fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for people with unresectable, locally advanced pancreatic cancer.

In September 2020, Immunovia AB announced positive results from its verification study for the launch of IMMray PanCan-d. IMMray PanCan-d is slated to be the first blood-based test used for the early diagnosis of pancreatic cancer.

In September 2020, scientists from the University of Sheffield discovered a drug that can improve the life expectancy and quality of life for patients with hard-to-treat pancreatic cancer.

In May 2020, scientists from the Weill Cornell Medicine and the Beth Israel Deaconness Medical Center announced positive results from its COMBAT trial. The trial is studying the use of triple combination of an investigational drug called BL- 8040 (motixafortide), which can be used to treat metastatic pancreatic cancer.

In June 2019, AstraZeneca and Merck & Co. developed and commercialized a drug sold under the brand name LYNPARZA (Olaparib). Their international Phase-III trial study found that treatment with the drug Olaparib significantly reduced the risk of disease progression or death.